Selinexor (KPT-330)

Catalog No.S7252 Batch:S725201

Print

Technical Data

Formula

C17H11F6N7O
Molecular Weight 443.31 CAS No. 1393477-72-9
Solubility (25°C)* In vitro DMSO 89 mg/mL (200.76 mM)
Ethanol 40 mg/mL (90.23 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Selinexor (KPT-330, ATG-010) is an orally bioavailable selective CRM1 inhibitor. Phase 2.
Targets
CRM1 [1]
(Cell-free assay)
In vitro As the clinical candidate analog of KPT-185, KPT-330 exhibits similar effects on the viability of T-ALL cells and elicits rapid apoptotic response. KPT-330 also reduces cell growth in MOLT-4, Jurkat, HBP-ALL, KOPTK-1, SKW-3, and DND-41 cell lines, with IC50 values of 34-203 nM. [1]
In vivo KPT-330 dramatically suppresses the growth of T-ALL cells (MOLT-4) and AML cells (MV4–11) in vivo, with little toxicity to normal haematopoietic cells. [1] In SCID mice with diffuse human MM bone lesions, KPT-330 inhibits MM-induced bone lysis and prolongs survival. Moreover, KPT-330 directly impairs osteoclastogenesis and bone resorption by blocking RANKL-induced NF-κB and NFATc1, with minimal impact on osteoblasts and BMSCs. [2]

Protocol (from reference)

Cell Assay:[1]
  • Cell lines

    MOLT-4, Jurkat, HBP-ALL, KOPTK-1, SKW-3, and DND-41 cell lines

  • Concentrations

    ~1 μM

  • Incubation Time

    72 hours

  • Method

    Cell lines are cultured in RPMI 1640 medium, supplemented with 10% fetal bovine serum and penicillin/streptomycin. Cell Titer Glo assay is used to assess cell viability upon treatment with either dimethyl sulfoxide (DMSO) or KPT-330. Cells are plated at a density of 10 000 cells per well in a 96-well plate and incubated with DMSO or increasing concentrations of KPT-330. The cell viability is measured after 72 h exposure to KPT-330 and reported as a percentage of DMSO control cells. Jurkat cells that overexpress BCL2 are generated using MSCV-IRES-GFP retroviral expression system. Jurkat cells infected with BCL2 or control vector viruses are sorted by flow cytometry and the expression of BCL2 confirmed by Western blot analysis using BCL2 antibody.
Animal Study:[1]
  • Animal Models

    T-ALL and AML orthograft mouse model

  • Dosages

    20 -25 mg/kg

  • Administration

    p.o.

Customer Product Validation

, , Mol Cancer Ther, 2017, 16(4):717-728

Data from [Data independently produced by , , J Cell Mol Med, 2018, doi:10.1111/jcmm.13886]

Data from [Data independently produced by , , BMC Cancer, 2018, 18(1):764]

Data from [Data independently produced by , , Biochem Biophys Res Commun, 2018, 503(3):1773-1779]

Selleck's Selinexor (KPT-330) has been cited by 121 publications

A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities [ Cell Rep Med, 2025, S2666-3791(25)00102-8] PubMed: 40147445
NPM1-fusion proteins promote myeloid leukemogenesis through XPO1-dependent HOX activation [ Leukemia, 2025, 39(1):75-86] PubMed: 39443736
Atovaquone and selinexor as a novel combination treatment option in acute myeloid leukemia [ Cancer Lett, 2025, 613:217501] PubMed: 39864539
Targeting fucosyltransferase FUT8 as a prospective therapeutic approach for DLBCL [ Oncogenesis, 2025, 14(1):1] PubMed: 39881135
Regulation of chromatin modifications through coordination of nucleus size and epithelial cell morphology heterogeneity [ Commun Biol, 2025, 8(1):269] PubMed: 39979587
Discovery of non-steroidal aldo-keto reductase 1D1 inhibitors through automated screening and in vitro evaluation [ Toxicol Lett, 2025, 406:31-37] PubMed: 39988211
MYC networks associate with decreased CD8 T-cell presence in diffuse large B-cell lymphoma and may be addressed by the synergistic combination of AZD4573 and Selinexor - a preliminary analysis [ Ann Hematol, 2025, 10.1007/s00277-025-06298-x] PubMed: 40064656
Efficacy and mechanism of the XPO1 inhibitor selinexor combined with decitabine in T-cell lymphoblastic lymphoma [ Ann Hematol, 2025, none] PubMed: 40014082
Dual Inhibition of CDK4/6 and XPO1 Induces Senescence With Acquired Vulnerability to CRBN-Based PROTAC Drugs [ Gastroenterology, 2024, S0016-5085(24)00062-3] PubMed: 38262581
p300 nucleocytoplasmic shuttling underlies mTORC1 hyperactivation in Hutchinson-Gilford progeria syndrome [ Nat Cell Biol, 2024, 10.1038/s41556-023-01338-y] PubMed: 38267537

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.